San Diego-based Regulus Therapeutics has adjusted its anticipated IPO terms, saying in a filing this morning that it now anticipates its initial public offering price of its stock to be $4.00 per share, and that it will offer up 11.25M shares to the public in its IPO. The firm had initially been targeted at offering 4.5M shares of its stock at between $10.00 and $12.00 per share. Regulus is a developer of microDNA-based biopharmaceuticals.